Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Dose Telavancin in Pediatric Subjects
NCT02013141Phase 1Terminated
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Mar 2021
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telavancin in Gram-positive bacterial infection, sponsored by Cumberland Pharmaceuticals. Primary endpoints: Area Under the Curve Extrapolated to Infinity at 24 hours, Maximum Plasma Concentration at 24 hours and 3 more. Started Dec 2014; status: terminated.
02
Drugs
telavancin
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT02013141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013141.